Complete two-year follow-up with formal non-inferiority testing on primary outcomes of the AIDA trial comparing the Absorb bioresorbable scaffold with the XIENCE drug-eluting metallic stent in routine PCI

Ruben Y.G. Tijssen1, MD; Robin P. Kraak1,2, MD; Sjoerd H. Hofma3, MD, PhD; Rene J. van der Schaaf2, MD, PhD; E. Karin Arkenbout4, MD, PhD; Auke Weevers5, MD; Joelle Elias1, MD; Ivo M. van Dongen1, MD; Karel T. Koch1, MD, PhD; Jan Baan Jr1, MD, PhD; M. Marije Vis1, MD, PhD; Robbert J. de Winter1, MD, PhD; Jan J. Piek1, MD, PhD; Jan G.P. Tijssen1, PhD; Jose P.S. Henriques1, MD, PhD; Joanna J. Wykrzykowska1*, MD, PhD

1. AMC Heartcenter, Academic Medical Center - University of Amsterdam, Amsterdam, the Netherlands; 2. Department of Cardiology, Onze Lieve Vrouwe Gasthuis, Amsterdam, the Netherlands; 3. Department of Cardiology, Medical Center Leeuwarden, Leeuwarden, the

Aims: The aim of this report of the AIDA trial is to provide full two-year outcomes for the primary endpoint of target vessel failure (TVF) and an update on device thrombosis.

Sign in to read and download the full article

Login Forgot your password?

No account yet? Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Share on Facebook Share on Twitter Share on Linkedin

Read next article

Implantation techniques (predilatation, sizing, and post-dilatation) and the incidence of scaffold thrombosis and revascularisation in lesions treated with an everolimus-eluting bioresorbable vascular scaffold: insights from the AIDA trial